A Phase 2 interventional study of disitamab vedotin and pembrolizumab in Urothelial Carcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Recruiting at 221 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell — 5 open to participants now, 6 under way, 2 of them phase 3. disitamab vedotin · Carcinoma, Transitional Cell.
Among the 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 2, and was the 5th registered.
632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →5 of the 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell are open now, in 12 countries. Recruiting first, the newest first:
Shanxi Province Cancer Hospital · Sites in China
Ages 18+
Chunguang yang (101937) · Sites in China
Ages 18–75
RemeGen Co., Ltd. · Sites in China
Ages 18+
Wuhan Union Hospital, China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 2 · Phase 4 1
First in 2017; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 372 is above the median of 50 across 500 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 40 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 6 most frequent:
This study is registered under Seagen, a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
14 studies in Carcinoma, Transitional Cell by Pfizer: 4 open now, 5 under way, 1 of them phase 3. Of 9 finished, 4 (44%) have results posted.
Among the 14 studies in Carcinoma, Transitional Cell by Pfizer, this one is the only one that started in 2022, is the only one in phase 2, and was the 6th registered.
Pfizer’s Carcinoma, Transitional Cell studies by the year they started, since 2016.
3 of the studies testing disitamab vedotin in Carcinoma, Transitional Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05302284Phase 3RemeGen Co., Ltd.A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | 2026-12-31 |
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT04879329Seagen, a wholly owned subsidiary of PfizerA Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | 2026-12-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 14 in Carcinoma, Transitional Cell:
This tab as a report to print or save as PDF → With an account.
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohorts A and B
Cohort C
No prior systemic therapy for LA/mUC
Cohort D
Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following for LA/mUC:
Cohort E
No prior systemic therapy for LA/mUC
Cohort G
Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of therapy containing enfortumab vedotin as monotherapy or in combination with pembrolizumab
Exclusion Criteria:
Cohorts A and B
Cohort C
Cohort D
Cohort E
Cohort G
There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Disitamab vedotin monotherapy
Drug: disitamab vedotin
Disitamab vedotin monotherapy
Drug: disitamab vedotin
Disitamab vedotin + pembrolizumab
Drug: disitamab vedotin · Drug: pembrolizumab
Disitamab vedotin + pembrolizumab
Drug: disitamab vedotin · Drug: pembrolizumab
Disitamab vedotin monotherapy
Drug: disitamab vedotin
Disitamab vedotin monotherapy
Drug: disitamab vedotin
Disitamab vedotin + pembrolizumab
Drug: disitamab vedotin · Drug: pembrolizumab
Disitamab vedotin
Drug: disitamab vedotin
Given into the vein (IV; intravenous) every 2 weeks.
Also known as: RC48-ADC
Given by IV on Day 1 of each 6-week cycle.
Also known as: KEYTRUDA®
Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, C, and G)
The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1
Time frame: Duration of treatment; approximately 2 years
Incidence of adverse events (AEs) (Cohorts D and E)
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Time frame: Approximately 2 years
Incidence of dose alterations (Cohorts D and E)
Time frame: Approximately 2 years
Incidence of laboratory abnormalities (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Approximately 2 years
Incidence of electrocardiogram (ECG) abnormalities (Cohorts D and E)
Time frame: Approximately 2 years
Change from baseline of left ventricular ejection fraction (LVEF) (Cohorts D and E)
Time frame: Approximately 2 years
Pharmacokinetic (PK) parameter - Area under the curve (AUC) (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Maximum concentration (Cmax) (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Time to maximum concentration (Tmax) (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Trough concentration (Ctrough) (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
cORR per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)
The proportion of participants with confirmed CR or PR according to RECIST v1.1
Time frame: Duration of treatment; approximately 2 years
Confirmed Duration of Response (DOR) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)
The time from first documentation of objective tumor response (confirmed CR or PR) to the first documentation of tumor progression per RECIST v1.1 or death due to any cause.
Time frame: From start of treatment to completion of response assessment; approximately 2 years
Confirmed DOR per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)
The time from first documentation of objective tumor response (confirmed CR or PR) to the first documentation of tumor progression per RECIST v1.1 or death due to any cause.
Time frame: From start of treatment to completion of response assessment; approximately 2 years
Progression-free survival (PFS) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)
The time from the start of study treatment or randomization (if applicable) to the first documentation of disease progression per RECIST v1.1 or death due to any cause.
Time frame: From start of treatment to completion of response assessment; approximately 2 years
PFS per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)
The time from the start of study treatment or randomization (if applicable) to the first documentation of disease progression per RECIST v1.1 or death due to any cause.
Time frame: From start of treatment to completion of response assessment; approximately 2 years
Disease control rate (DCR) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)
The proportion of participants who have achieved objective response (confirmed CR or PR as per RECIST v1.1 criteria) or stable disease (SD) lasting at least 5 weeks.
Time frame: From start of treatment to completion of response assessment; approximately 2 years
DCR per RECIST v1.1 by investigator (Cohorts A, B, C, and G)
The proportion of participants who have achieved objective response (confirmed CR or PR as per RECIST v 1.1 criteria) or SD lasting at least 5 weeks.
Time frame: From start of treatment to completion of response assessment; approximately 2 years
Overall survival (OS) (Cohorts A, B, C, and G)
The time from start of study treatment or randomization (if applicable) to the date of death due to any cause.
Time frame: Duration of study; approximately 3 years
Incidence of adverse events (AEs) (Cohorts A, B, C, and G)
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Time frame: Approximately 2 years
Incidence of dose alterations (Cohorts A, B, C, and G)
To be summarized using descriptive statistics.
Time frame: Approximately 2 years
Incidence of laboratory abnormalities (Cohorts A, B, C, and G)
To be summarized using descriptive statistics.
Time frame: Approximately 2 years
Incidence of ECG abnormalities (Cohorts A, B, C, and G)
Time frame: Approximately 2 years
Change from baseline of LVEF (Cohorts A, B, C, and G)
Time frame: Approximately 2 years
PK parameter - AUC (Cohorts A, B, C, and G)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Cmax (Cohorts A, B, C, and G)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Tmax (Cohorts A, B, C, and G)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Ctrough (Cohorts A, B, C, and G)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter of pembrolizumab - Cmax (Cohort E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
Incidence of anti-drug antibodies (ADAs) against disitamab vedotin (All Cohorts)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
Incidence of anti-drug antibodies (ADAs) against pembrolizumab (Cohorts C and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
Incidence of neutralizing antibodies (NABs) against disitamab vedotin (All Cohorts)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 221 sites across 12 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.
Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's planned 55 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Disitamab vedotin
Carcinoma, Transitional Cell →
Seagen, a wholly owned subsidiary of Pfizer →